Sandur Manganese & Iron Ores Ltd has approved the incorporation of Royal Sandur MedTech Private Limited as a wholly owned subsidiary with an initial investment of ₹1 crore. The move marks the company's entry into the medical devices and healthcare consumables business, expanding beyond its traditional mining and ferroalloys operations. Investors should watch how the company executes this diversification strategy and whether further investments follow.
Sandur Manganese Approves ₹1 Crore Investment in MedTech Subsidiary
Investment: ₹1 crore
Ownership: 100% in Royal Sandur MedTech Private Limited
Reader Takeaway: Diversification opens a new growth avenue, but execution outside the core mining business remains the key challenge.
What just happened
Sandur Manganese & Iron Ores Ltd (SMIORE) has approved the incorporation of a wholly owned subsidiary, Royal Sandur MedTech Private Limited, following a board meeting held on September 17, 2026.
The company will invest ₹1 crore by subscribing to 10,00,000 equity shares with a face value of ₹10 each through a cash investment. The incorporation remains subject to applicable statutory and regulatory approvals.
The new subsidiary will undertake the manufacturing, processing, assembly, marketing and distribution of medical devices, surgical products, diagnostic products and healthcare consumables.
Why this matters
The decision marks SMIORE's formal entry into the healthcare and medical devices sector. Until now, the company has primarily operated in mining and ferroalloys.
The move broadens the company's business portfolio and creates an additional platform for future growth outside commodity-linked businesses. However, the initial investment is relatively modest, indicating that the diversification is beginning on a measured scale.
The backstory
The latest announcement follows the company's disclosure on July 9, 2026, when it informed investors of its intention to diversify into new business segments.
The incorporation of Royal Sandur MedTech Private Limited represents the first concrete step in implementing that strategy.
What changes now
Following incorporation, Royal Sandur MedTech Private Limited will become a 100% owned subsidiary of Sandur Manganese & Iron Ores Ltd.
The subsidiary will focus on medical devices, diagnostic products, surgical products and healthcare consumables, expanding the group's business profile beyond metals and mining.
Risks to watch
The company is entering an industry outside its traditional operating domain.
Investors should monitor:
- Completion of incorporation and regulatory approvals.
- Appointment of management and operational leadership.
- Future capital allocation into the subsidiary.
- Commercial timelines for commencing operations.
- The financial contribution of the new business over the medium term.
What to track next
Key future disclosures will include completion of incorporation, commencement of business activities, additional investments, manufacturing plans and any strategic partnerships that support the healthcare venture.